Transcranial Magnetic Stimulation in Treatment of Attention Deficit/Hyperactivity Disorders

Transcranial Magnetic Stimulation of the Pre-Frontal Cortex in the Treatment of Attention Deficit/Hyperactivity Disorders: A Randomized, Controlled, Double Blind Study.

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01618110

Enrollment

Registered

2012-06-13

Start date

2012-07-31

Completion date

2014-07-31

Last updated

2012-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit/Hyperactivity Disorder

Keywords

ADHD, Attention Deficit/Hyperactivity Disorder, TMS, Transcranial Magnetic Stimulation

Brief summary

* ADHD is one of the most common psychiatric disorders. * While most of the attention is directed towards youth, 60% continue to suffer symptoms into adult life. * Current treatment is effective, but 30% suffer side effects that lowers QOL, and 20% are non-responders. * Known mechanism of pathophysiology includes hypoactive dopaminergic system, especially at right PFC. * It is this study hypothesis that by stimulating the right PFC by TMS, it will be possible to alleviate ADHD symptoms. * A 10 sessions of treatment will by applied on a randomly allocated group of patients, diagnosed with ADHD, in a 2:1 ratio: The first group will receive an actual TMS treatment, and the second group will receive a sham treatment. * Improvement of objective and subjective ADHD scale will be examined.

Interventions

DEVICETranscranial Magnetic Stimulation (Magstim, Rapid)

Superficial rTMS, directed at right PFC, power of 100% of MT, 10Hz for 4 seconds, intervals of 30 seconds, 42 trains.

OTHERPlacebo Treatment

Sham coil (minimal magnetic field, same noise and feeling)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

21 Years to 50 Years

Healthy volunteers

Inclusion criteria

* Age 18-50 * Established diagnosis of ADHD * No C/I for TMS * Has signed an informed consent form

Exclusion criteria

* Major Psychiatric disorders (Psychotic or Affective) * Active use of drugs (4 weeks prior to participation) * Neurologic disorder such as Epilepsy. * No use of stimulants during the previous 7 days

Countries

Israel

Contacts

Primary ContactAviv Segev, MD

aviv.segev@clalit.org.il972-9-7478-644

Backup ContactYuval Bloch, MD

yuvalbl@clalit.org.il972-9-7478-510

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026